网站首页期刊介绍通知公告编 委 会投稿须知电子期刊广告合作联系我们
最新消息:
非小细胞肺癌中PFN2的表达及其与铂类化疗敏感性的关系
作者:余宏伟  张一斌  张璐  廖志伟  林晓丹  周同冲 
单位:广州医科大学附属肿瘤医院 放疗科, 广东 广州 510095
关键词:非小细胞肺癌 肌动蛋白结合蛋白2 铂类化疗 
分类号:R734.2
出版年·卷·期(页码):2021·49·第八期(932-937)
摘要:

目的:探讨非小细胞肺癌(NSCLC)癌组织中肌动蛋白结合蛋白2(PFN2)的表达及其与铂类化疗敏感性的关系。方法:选取2014年4月至2017年3月在本院肿瘤科经气管镜或肺穿刺活检病理组织学诊断确诊的NSCLC患者128例作为研究对象,均接受铂类化疗药物治疗,收集患者手术过程中切除的癌组织及癌旁正常组织,免疫组化法检测癌组织及癌旁组织中PFN2的表达情况;分析PFN2阴阳性表达与临床病理特征的相关性;卡方检验分析PFN2阴、阳性表达与铂类化疗客观有效率的关系;Kaplan-Meier法分析PFN2与NSCLC患者3年生存期的关系;多因素COX回归模型分析影响患者预后的因素。结果:NSCLC腺癌、鳞癌组织中PFN2阳性率明显高于癌旁正常组织(85.9%vs 12.5%、89.8%vs 10.8%,均P<0.05)。NSCLC癌组织中PFN2表达与肿瘤远处转移、TNM分期、淋巴结转移有关(P<0.05)。PFN2阴性表达患者治疗有效率高于PFN2阳性表达患者(62.00%vs 21.79%,P<0.05)。Kaplan-Meier分析结果显示,PFN2阳性表达患者3年生存率低于PFN2阴性表达患者(48.72%vs 72.00%,Log-rank χ2=9.548,P<0.005)。多因素COX分析显示,PFN2阳性的HR为0.759(95%CI为0.608~0.947)是影响NSCLC患者预后良的危险因素(P<0.05)。结论:PFN2在NSCLC患者癌组织中PFN2阳性率较高,与肿瘤远处转移、TNM分期、淋巴结转移及铂类化疗客观有效率密切相关。

Objective: To investigate the expression of profilin-2(PFN2) in non-small cell lung cancer(NSCLC) and its relationship with platinum sensitivity.Methods: From April 2014 to March 2017, 128 patients with NSCLC diagnosed by tracheoscopy or lung biopsy in the oncology department ofour hospital were selected as the research objects. All patients were treated with platinum chemotherapy drugs. The cancer tissues and normal adjacent tissues were collected during the operation, the expression of PFN2 in cancer tissues and adjacent normal tissues was detected by immunohistochemistry; the correlation between the positive and negative expressions of PFN2 and clinicopathological features was analyzed; Chi square test was used to analyze the relationship between the positive and negative expressions of PFN2 and the objective response rate of platinum chemotherapy; Kaplan-Meier method was used to analyze the relationship between PFN2 and 3-year survival in patients with NSCLC; and multivariate COX regression model was used to analyze the influencing factors ofprognosis.Results: The positive rate of PFN2 in NSCLC adenocarcinoma tissues and squamous cell carcinoma tissues was significantly higher than that in adjacent normal tissues(85.9% vs 12.5%, 89.8% vs 10.8%, P<0.05). The expression of PFN2 in NSCLC was correlated with distant metastasis, TNM stage and lymph node metastasis(P<0.05). The effective rate of patients with negative expression of PFN2 was higher than that of patients with positive expression of PFN2(62.00% vs 21.79%, P<0.05). Kaplan-Meier analysis showed that the 3-year survival rate of patients with positive expression of PFN2 was lower than that of patients with negative expression of PFN2(48.72% vs 72.00%, Log-rank χ2=9.548, P<0.005). Multivariate COX analysis showed that PFN2 positive HR 0.759(95%CI:0.608-0.947) was a risk factor for prognosis of NSCLC patients(P<0.05). Conclusion: The positiverate of PFN2 in cancer tissues of NSCLC patients was higher, which is closely related to distant metastasis, TNM stage, lymph node metastasis and objective response rate of platinum chemotherapy.

参考文献:

[1] FERLAY J, SOERJOMATARAM I, DIKSHIT R, et al. Cancer incidence and mortality worldwide:sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015, 136(5):E359-E386.
[2] 张玉双, 李晶.晚期非小细胞肺癌真实世界研究现状[J]. 中国全科医学, 2020, 23(21):2607-2614.
[3] SIEGEL R, NAISHADHAM D, JEMAL A.Cancer statistics, 2013[J]. CA Cancer J Clin, 2013, 63(1):11-30.
[4] ALLEMANI C, WEIR H K, CARREIRA H, et al. Global surveillance of cancer survival 1995-2009:analysis of individual data for 25, 676, 887 patients from 279 population-based registries in 67 countries(CONCORD-2)[J]. Lancet, 2015, 385(9972):977-1010.
[5] 唐翠萍, 秦思, 伍万春, 等.Ⅲa期非小细胞肺癌新辅助化疗的疗效分析及应用价值[J]. 中国肺癌杂志, 2017, 20(2):100-106.
[6] ZHANG H, YANG W, YAN J, et al. Loss of profilin 2 contributes to enhanced epithelial-mesenchymal transition and metastasis of colorectal cancer[J]. Int J Oncol, 2018, 53(3):1118-1128.
[7] KIM M J, LEE Y S, HAN G Y, et al. Profilin 2 promotes migration, invasion, and stemness of HT29 human colorectal cancer stem cells[J]. Biosci Biotechnol Biochem, 2015, 79(9):1438-1446.
[8] 王蓉, 李大鹏, 冯军.参麦注射液联合化疗对晚期非小细胞肺癌患者T细胞亚群及细胞因子的影响[J]. 南京中医药大学学报, 2016, 32(2):125-128.
[9] 李静, 袁涛, 秦冬梅, 等.小分子酪氨酸激酶抑制剂治疗非小细胞肺癌的回顾性分析[J]. 中国药房, 2016, 27, 48(2):213-215.
[10] ENG L, HARðRDOTTíR H, SONG H, et al. Mortality of lung cancer as a second primary malignancy:a population-based cohort study[J]. Cancer Med, 2019, 8(6):3269-3277.
[11] 霍云丽, 郭子建.肺癌自身抗体在肿瘤早期诊断和治疗中的临床应用进展[J]. 标记免疫分析与临床, 2019, 26(5):887-891.
[12] 王娜娜, 江楠, 杨晓庆, 等.非小细胞肺癌组织起源分子病理分类及其临床意义[J]. 中国肺癌杂志, 2018, 21(7):41-46.
[13] LIU H, REN G, WANG T, et al. Aberrantly expressed Fra-1 by IL-6/STAT3 transactivation promotes colorectal cancer aggressiveness through epithelial-mesenchymal transition[J]. Carcinogenesis, 2015, 36(4):459-468.
[14] WU T, HU H, ZHANG T, et al. miR-25 promotes cell proliferation, migration, and invasion of non-small-cell lung cancer by targeting the LATS2/YAP signaling pathway[J]. Oxid Med Cell Longev, 2019, 2019:9719723.
[15] KÖNIG K, MEDER L, KRÖGER C, et al. Loss of the keratin cytoskeleton is not sufficient to induce epithelial mesenchymal transition in a novel KRAS driven sporadic lung cancer mouse model[J]. PLoS One, 2013, 8(3):e57996.
[16] YAN J, MA C, GAO Y.MicroRNA-30a-5p suppresses epithelial-mesenchymal transition by targeting profilin-2 in high invasive non-small cell lung cancer cell lines[J]. Oncol Rep, 2017, 37(5):3146-3154.
[17] 孙慧, 陈风.anillin肌动蛋白结合蛋白在肿瘤中作用的研究进展[J]. 癌症进展, 2019, 17(7):752-753, 764.
[18] ZHOU K, CHEN J, WU J, et al. Profilin 2 promotes proliferation and metastasis of head and neck cancer cells by regulating PI3K/AKT/_-Catenin signaling pathway[J]. Oncol Res, 2019, 27(9):1079-1088.
[19] 王茜, 李光辉, 郭嘉, 等.miR-199b-5p在头颈癌细胞中的表达及对细胞增殖和侵袭能力的影响[J]. 上海口腔医学, 2018, 27(3):265-269.
[20] CUI X B, ZHANG S M, XU Y X, et al. PFN2, a novel marker of unfavorable prognosis, is a potential therapeutic target involved in esophageal squamous cell carcinoma[J]. J Transl Med, 2016, 14(1):137.

服务与反馈:
文章下载】【发表评论】【查看评论】【加入收藏
提示:您还未登录,请登录!点此登录
您是第 730295 位访问者


 ©《现代医学》编辑部
联系电话:025-83272481;83272479
电子邮件: xdyx@pub.seu.edu.cn

苏ICP备09058541